Depakine Chrono

Quick links

Choose a section

Quick links to important sections

Advertisements

Depakine Chrono

Selected form

Advertisements
Advertisements

Overview of Depakine Chrono

Quick Facts

Property Description
Active ingredient Valproic Acid
Form Prolonged-release tablet
Pharmacological class Antiepileptic Drug (AED) / Anticonvulsant
Origin Synthetic compound

What Type of Medicine is Depakine Chrono?

Depakine Chrono is a synthetic pharmacological preparation classified as a broad-spectrum Antiepileptic Drug (AED), which functions as an anticonvulsant. The core chemical entity, Valproic Acid, is a fatty acid derivative identified under the ATC classification code N03AG01. It is a clinically recognized agent for providing fundamental neurological stabilization, particularly in patients requiring consistent control over electrical brain activity. As a prescription-only medicine, it is utilized for its efficacy across multiple forms of neuronal instability.

Composition and The Function of the Prolonged-Release Tablet

The active ingredient in this medication is Valproic Acid (INN), delivered as Valproate Semisodium to ensure controlled release and stability upon oral administration. This medicine is distinctively supplied as a prolonged-release tablet, a specialized modified-release technology. The term "Chrono" signifies that the formulation is engineered to dispense the active ingredient slowly and consistently over many hours. This design ensures that controlled-release formulations maintain consistent serum levels, which helps minimize fluctuations associated with rapid absorption. This delivery system provides a steady, therapeutic presence essential for long-term management.

High-Level Purpose: How It Achieves Stability

The drug’s core purpose is to diminish excessive or abnormal electrical signaling, thereby promoting generalized stability of neuronal excitability. It achieves this by modulating key neurochemical systems, notably by increasing the inhibitory neurotransmitter \gamma-aminobutyric acid (GABA), which naturally acts as the brain's calming agent. This means the medicine helps quiet overactive nerve cells, providing a reliable baseline of neurological control for patients requiring consistent, long-term therapeutic management.

Regulatory References

  1. European Medicines Agency (Valproate referral)
Advertisements

What side effects are possible with Depakine Chrono?

Possible Side Effects and Safety Information

The safety profile of Depakine Chrono (Valproic Acid) is officially classified by regulatory agencies based on the frequency and the organ system affected, providing a structured understanding of its risks.

Official Safety Classifications

Classification Representative Adverse Reactions
Very Common (ge 10% incidence) Nausea, Tremor, Somnolence, Asthenia (weakness), Headache.
Common (1% to <10% incidence) Diarrhea, Abdominal pain, Weight change (gain or loss), Alopecia (hair loss), Dizziness, Thrombocytopenia (low platelet count).

Adverse reactions are also categorized by System-Organ-Class, including Gastrointestinal Disorders, Nervous System Disorders, and Hepatobiliary Disorders.

Documented Serious Adverse Reactions

Regulatory documents highlight several serious safety concerns that are not directly dose-related and may occur at any time during treatment, although some are more common initially. These include the potential for Fatal Hepatotoxicity (severe liver failure), which usually occurs during the first six months of treatment, and life-threatening Pancreatitis (inflammation of the pancreas). Additionally, Valproic Acid carries the documented risk of Hyperammonemic Encephalopathy (brain dysfunction due to high ammonia levels) and, like other Antiepileptic Drugs, an increased risk of Suicidal Behavior and Ideation.

Population-Specific Safety Notes

The medicine is associated with significant teratogenic risk (birth defects) and neurodevelopmental impairment when used by women during pregnancy, a key constraint noted in all regulatory labeling. Furthermore, children under the age of two are at a considerably increased risk of fatal hepatotoxicity, and older adults may exhibit increased sensitivity to effects like somnolence.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

The information in this section is derived from official government regulatory documents detailing the overdose profile of Valproic Acid.


Overdose Manifestations and Severe Outcomes

Overdose of Depakine Chrono is characterized primarily by profound Central Nervous System (CNS) depression, presenting as somnolence, lethargy, confusion, and potential progression to a deep, calm coma. Officially documented neurological signs include muscular hypotonia, miosis, and hyporeflexia. Severe, life-threatening outcomes reported in regulatory literature include respiratory depression, hypotension leading to circulatory collapse, and critical metabolic events such as metabolic acidosis, hyperammonemic encephalopathy, and cerebral oedema. Massive ingestion has been associated with multi-system organ failure and death.


Required Emergency Actions

Immediate medical attention or emergency medical care must be sought for any suspected overdose due to the risk of life-threatening complications. Treatment requires management in a hospital setting. Regulatory documents state that no specific antidote is known for Valproic Acid overdose. Management involves general symptomatic and supportive treatment, with mandatory continuous cardiorespiratory monitoring. Supportive procedures may include considering gastric lavage or activated charcoal. In serious cases, extra-renal purification (e.g., hemodialysis) may be necessary to remove the drug from the body, as documented in official prescribing information.

Advertisements

Therapeutic Uses of Depakine Chrono

Depakine Chrono, which contains Valproic Acid, is a pharmaceutical preparation that provides supportive relief across domains involving certain distressing symptoms. The medication is generally used across three primary therapeutic domains where managing symptoms associated with acute or episodic changes is relevant.

This medicine is commonly used for managing various types of epilepsy (including generalized and partial seizure disorders), stabilizing manic episodes in bipolar disorder, and serving as prophylaxis for frequent migraine headaches. The key benefit is providing support that helps ease the overall symptom burden by contributing to symptom management, which assists with maintaining functional stability.

“Applied across domains where additional symptomatic support is needed, this medicine helps manage groups of symptoms that may become intense or disruptive in chronic conditions.”

The support provided is relevant for easing distress and may assist patients with managing symptom fluctuations. It is commonly used in clinical settings that involve acute or unstable symptom patterns, and may be part of symptomatic management in long-term maintenance therapy.


Quick Fact: Supportive Management for Episodic Symptoms

Primary Focus Symptom Category Primary Support Focus Clinical Use
Stabilizing neurological excitability. Symptoms that create noticeable physiological strain (seizures, migraines), and symptoms related to heightened physiological activity (mania). Supports the patient by easing distress and assisting with maintaining functional stability. Applied during phases when symptoms become more noticeable and supportive symptom management is appropriate.

Regulatory References

  1. NIH MedlinePlus overview
Advertisements

Eligibility and Restrictions for Use

This section outlines the eligibility and non-eligibility criteria for Depakine Chrono (valproate), as defined by official regulatory bodies, such as the FDA and EMA.

Contraindicated Populations

Depakine Chrono must not be used by individuals with:

  • Hepatic disease or significant hepatic dysfunction (acute or chronic hepatitis).
  • Urea cycle disorders.
  • Mitochondrial disorders caused by mutations in mitochondrial DNA polymerase gamma (POLG), including children under two years old suspected of having such a disorder.
  • Known hypersensitivity or allergy to valproate or any of its components.
  • Hepatic porphyria.

Age and Formulation Restrictions

  • Children under two years of age are at a considerably increased risk of fatal hepatotoxicity and require extreme caution if use is deemed essential.
  • The prolonged-release tablet (Chrono) formulation is generally not suitable for children under six years or those weighing less than 20 kg due to the risk of choking and difficulties with dose adjustment.
  • Safety and efficacy for certain seizures are not established in children younger than ten years.
  • Elderly patients should be started on a reduced dose due to a greater sensitivity to side effects like drowsiness.

Pregnancy and Reproductive Restrictions

Pregnancy: The medicine is contraindicated for pregnant women being treated for bipolar disorder or migraine prophylaxis. For epilepsy, it is contraindicated during pregnancy unless there is no suitable alternative treatment.

Women and girls of childbearing potential (WOCBP) must not use the medicine unless the conditions of a comprehensive Pregnancy Prevention Program (PPP) are strictly met, including specialist review and effective contraception.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Valproic Acid through specific pharmacokinetic and pharmacodynamic patterns, resulting in formal restrictions on co-administration.


Documented Interaction Patterns

Valproic Acid's exposure is affected by several medicinal products. Hepatic enzyme-inducing agents, such as Phenytoin and Carbamazepine, are officially documented to increase Valproate clearance, which can potentially lower its plasma concentration. Conversely, substances like Felbamate may decrease Valproate clearance, leading to increased exposure. Aspirin (salicylates) is also noted to increase Valproic Acid plasma levels due to competition for plasma protein binding sites.

Clinically Significant Restrictions

Certain combinations carry severe, officially documented warnings. The co-administration of Carbapenem antibiotics (e.g., Meropenem) is associated with a rapid and substantial decrease in Valproate concentration, which can result in the loss of therapeutic control. Furthermore, combining Valproate with Topiramate is formally noted as being associated with an increased risk of hyperammonemia and encephalopathy.

Formal Contraindications and Substance Use

Valproate treatment is strictly contraindicated in patients with known Urea Cycle Disorders due to the severe risk of fatal hyperammonemic encephalopathy. The product information also states that alcohol intake is not recommended during treatment due to the potential for additive sedative effects.

Advertisements

Mechanism of Action

️ How Depakine Chrono Works

The action profile of Valproic Acid is broad-spectrum, engaging multiple molecular pathways to achieve stabilization of neural network activity. This pharmacodynamic effect is accomplished through three principal mechanistic domains.


Modulation of Neuronal Electrical Signaling

Valproic Acid exerts a direct influence on the electrical conductance of nerve cell membranes. The mechanism centers on blocking voltage-gated sodium and T-type calcium channels ( Na v, Ca v3. x). By restricting the influx of these ions, Valproic Acid inhibits abnormal high-frequency neuronal depolarization patterns, contributing to a reduction in abnormal electrical conductance.

Amplifying the Inhibitory GABAergic System

The compound amplifies the physiological activity of the GABAergic inhibitory pathway by focusing on GABA metabolism. It inhibits the enzyme GABA transaminase ( GABA-T), slowing down the catabolism of GABA, while simultaneously increasing its synthesis. This dual action elevates the functional concentration of the GABA neurotransmitter, resulting in increased central inhibitory tone.

Regulation of Gene Expression

This slower-onset mechanism involves the drug acting as an inhibitor of Histone Deacetylases ( HDACs). By altering the structure of chromatin, Valproic Acid facilitates the transcription of genes associated with neurotrophic factors and plasticity, contributing to sustained modulation of cellular plasticity pathways.

Advertisements

Dosage and Administration Information

The administration of Depakine Chrono (Valproic Acid Prolonged-Release Tablet) follows a structured protocol. The medication is designated for oral administration and is structurally defined as a prolonged-release tablet. Due to this specialized design, the tablet must be swallowed whole and must never be crushed, chewed, or masticated, which would compromise the controlled-release mechanism. To help mitigate potential gastric irritation, the medication should preferably be taken with meals.

The dosing schedule mandates a structured approach. The prolonged-release formulation is commonly administered once daily but may also be given in one to two divided doses per day. Treatment is initiated using a low starting dose, such as 600 mg/day or 10 -15 mg/kg/day for adults. The dose must undergo gradual titration, increasing incrementally over specified intervals (e.g., every few days or weekly) until the optimal maintenance range is reached, which often falls between 1000 -2000 mg/day. The maximum labeled daily dose typically does not exceed 2500 mg.

Specific rules for administration apply to certain populations. Older adults require individualized dosing based on clinical response and sensitivity. For children over 20 kg, the initial regimen starts at 400 mg/day. Furthermore, dosage reduction may be necessary in the presence of renal impairment. These administration parameters define the standardized protocol for the proper utilization of the medicine.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Depakine Chrono

Evidence for Use in Epilepsy and Seizure Disorders

Studies in conditions characterized by episodic or acute changes in electrical brain activity primarily use Randomized Controlled Trials (RCTs). These studies were designed to examine outcomes related to systemic or functional imbalance, such as the frequency of seizure events and the time until patients withdrew from the study. Research describes patterns where study participants, tracked over defined time intervals, showed changes in their seizure frequency. While evidence contributes to understanding symptom patterns in broad populations of adults and children, long-term effects are not fully established based on controlled, prospective research alone.

Evidence for Use in Acute Manic Episodes

Research exploring this medicine for conditions involving periods of heightened symptoms, such as acute mania in bipolar disorder, was initially conducted using short-term, placebo-controlled RCTs. These studies monitored outcomes linked to physiological strain or stress, using standardized clinical scales to measure symptom intensity. Findings describe patterns observed in these studies regarding how measured scores evolved in patients receiving the study medication. Limited information for long-term outcomes is available from studies with the highest level of certainty, as high-quality evidence focuses primarily on the acute treatment phase (typically lasting only a few weeks).

Evidence for Use in Migraine Headache Prophylaxis

The research base for this medicine’s study in frequent migraine headaches relies on prophylactic Randomized Controlled Trials (RCTs), often featuring a placebo control group. These studies primarily measured the change in the monthly frequency of migraine attacks in adult populations. A key limitation is that most controlled trials are of a short-term nature (typically lasting 3 to 6 months). The comparative evidence is lacking against many other available prophylactic options, and data on long-term durability is limited.

Research Gaps and Uncertainty

Research has been conducted in specific age groups, including children and adolescents with epilepsy. For older adults and patients presenting with comorbid conditions, evidence is primarily available from studies with small sample sizes or sub-group analyses. Overall, subgroup findings are uncertain for many less common presentations of the studied conditions. While short-term findings are generally well-defined, there is a lack of information for long-term outcomes regarding the sustained impact on daily functioning in controlled settings over many years.

Key Studies & References

  1. WHO Collaborating Centre for Drug Statistics Methodology: ATC Classification of the Nervous System (N03AG01)
  2. Valproic Acid: Drug Information - National Library of Medicine (NIH MedlinePlus)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Depakine Chrono (FAQ)

Q: How long does it typically take to feel the full effect of Depakine Chrono?

A: Official information indicates that treatment is started at a low amount and then gradually increased over a period of days or weeks until the optimal therapeutic level is reached. This process of gradual increase (known as titration) means that the full effect of the medication is not expected to be immediate.

Q: Is weight gain a common or expected side effect of Depakine Chrono?

A: According to the official product information, weight change (either gain or loss) is a common side effect, affecting between 1% and 10% of patients. This effect is recognized in the medication's safety profile.

Q: Is there a link between Depakine Chrono and hair loss?

A: Regulatory documents list alopecia (hair loss or thinning) as a common side effect of the medication, affecting between 1% and 10% of users. This is recognized in the official safety classification of the drug.

Q: Why is Depakine Chrono prescribed for migraines if it's an anti-epileptic?

A: Official product information states that Valproic acid is formally indicated (approved) for the prophylaxis, or prevention, of migraine headaches in adults. This is a licensed use for the medication, as well as treating seizure disorders and manic episodes associated with bipolar disorder.

Q: Can taking Depakine Chrono affect my menstrual cycle or fertility?

A: Official reports indicate a potential for reduced fertility in both men and women taking this medication. In women, it may also cause changes to the menstrual cycle, such as missed or delayed periods, and is linked to the risk of conditions like Polycystic Ovary Syndrome (PCOS).

Q: Are there any known interactions between Depakine Chrono and birth control pills?

A: Regulatory guidance suggests a moderate interaction with certain oral contraceptives that contain ethinyl estradiol. This interaction may potentially lead to a loss of seizure control for some users, and requires monitoring.

Q: How often do people taking Depakine Chrono need blood tests?

A: Official warnings state that routine blood tests, including complete blood counts and liver function tests, are required before and periodically during treatment. Monitoring is often done at frequent intervals, particularly during the first six months, to monitor for rare but serious adverse effects like liver failure.

Q: What should I do if I notice a skin rash after starting Depakine Chrono?

A: Official safety warnings state that signs of a serious allergic reaction, such as a persistent skin rash, fever, or swollen glands, require prompt medical attention. This is due to the potential for rare but serious hypersensitivity conditions.

Q: Does stopping Depakine Chrono suddenly have any risks?

A: Regulatory warnings state that treatment must not be stopped suddenly without the supervision of a healthcare provider. Abrupt discontinuation can increase the frequency or severity of seizures (seizure rebound) or trigger rebound mood symptoms.

Q: Does Depakine Chrono affect memory or concentration?

A: The official product information lists central nervous system (CNS) effects such as somnolence (drowsiness) and tremor as common side effects. Some regulatory documents note potential effects like difficulty concentrating or confusion.

Q: Is Depakine Chrono known to cause any emotional or mood changes?

A: Official warnings state that, like other anti-epileptic drugs, Valproic acid carries a warning about an increased risk of suicidal behavior and ideation. Other behavioral or mood changes reported include irritability, aggression, or agitation.

Q: How does Depakine Chrono affect sleep patterns?

A: Somnolence (feeling drowsy or sleepy) is listed as a very common side effect in the official product labeling. Conversely, insomnia (difficulty falling or staying asleep) is also sometimes noted as a common adverse effect.

Q: Why are folate supplements sometimes recommended with Depakine Chrono?

A: Regulatory sources indicate that Valproic acid can sometimes interfere with folate absorption or increase how quickly the body uses it. Taking folic acid supplements before and during early pregnancy is specifically recommended to help address risks like neural tube defects, particularly when used during pregnancy.

Q: Are there generic versions of Depakine Chrono available?

A: The active ingredient, Valproic Acid (delivered as Valproate Semisodium), is available under a variety of generic and branded formulations globally. These products contain the same core active component as Depakine Chrono.

Q: What are the long-term effects of Depakine Chrono on bone health?

A: Official safety updates warn that the long-term use of Valproate is associated with a reduction in bone density. This may increase the risk of reduced bone density, osteoporosis, and bone fractures.

Q: Are there any known issues with switching between different brands of the medication?

A: Regulatory authorities provide guidance that differences in absorption between brands may impact consistent seizure control. For patients on Valproate, this requires monitoring when changing products.

Q: Can Depakine Chrono be used for anxiety or other mood disorders?

A: Valproic acid is officially indicated for the treatment of bipolar disorder (specifically manic episodes and prophylaxis). It is not officially indicated by regulatory bodies for treating generalized anxiety disorder.

Advertisements

How should Depakine Chrono be stored and disposed of?

How to Store and Dispose of Depakine Chrono?

Depakine Chrono must be stored and handled according to specific regulatory requirements to maintain the integrity of its prolonged-release formulation.

Storage Requirements

  • Temperature and Protection: The medicine must be stored at room temperature, specifically below 25°C (or 77 F). It is a mandatory requirement to keep the product in its original container, which must be tightly closed to protect it from excessive moisture, heat, and direct light. The medicine must not be frozen.
  • Child Safety: A fundamental requirement is to store Depakine Chrono out of the sight and reach of children.

Disposal Instructions

Expired or unused Depakine Chrono must be managed as pharmaceutical waste. Disposal must strictly adhere to local environmental regulations and official protocols, such as drug take-back programs. The medicine must not be flushed down the toilet or discarded in standard household waste to prevent environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Depakine Chrono found in:

A-Z Index: